[ad_1]
Wednesday, September 09, 2020
“AZD1222” is a promising candidate for the development of a coronavirus vaccine. But the manufacturer Astrazeneca has to stop the clinical study because one of the participants is experiencing health problems.
The pharmaceutical company Astrazeneca stopped the clinical study of its corona vaccine as a precautionary measure after one of the participants developed health problems. The British company announced that it was a routine measure for these cases. “Diseases occur randomly in a large series of experiments, but they have to be independently investigated to prove it thoroughly.”
Astrazeneca will expedite the investigation so that the vaccine approval process is delayed as little as possible, he said. The ultimate goal of the review is to determine if the health problems were caused by the vaccine. During the arrest, no more study participants should be vaccinated and people who have been vaccinated should continue to be observed.
Unspecified health problems are an isolated case, the company stressed. The vaccine is currently in the third and final phase of the study with tens of thousands of participants. Known as “AZD1222,” the experimental vaccine is in late-stage clinical trials in the UK, Brazil and South Africa and is recognized as a leading candidate in the development of an effective coronavirus vaccine.
Astrazeneca and eight other pharmaceutical and biotech companies – Pfizer, Johnson & Johnson, Merck, Moderna, Novavax, Sanofi, and BionTech and GlaxoSmithKline – had only provided assurances Tuesday that they would not compromise safety by developing a corona vaccine. become. This unusual move came in light of concerns that there could be political pressure, especially in the US, to urgently approve the first vaccines before the November 3 presidential election. The president of the United States, Donald Trump, promises almost daily that there will be a vaccine by the end of the year or possibly by the time of the elections.
